CD27 and myeloid sarcoma: Early reports highlighted that some MS patients exhibit an expansion of “age-associated B cells” including double negative (IgD-/CD27-) B cells as well as CD21low B cells (11), which are now recognised to be primarily T-bet+ MBCs (10).